Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

BACKGROUND Influenza A/H9N2 viruses can infect humans and are considered to be a pandemic threat. Effective vaccines are needed for these and other avian influenza viruses. METHODS We performed a phase I, randomized, double-blind trial to evaluate the safety and immunogenicity of a 2-dose schedule (administered on days 0 and 28) of 4 dose levels (3.75, 7.5, 15, and 30 microg of hemagglutinin) of inactivated influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine with and without MF59 adjuvant. Vaccine safety was assessed with a diary and selected blood tests. Immunogenicity was measured using serum hemagglutination inhibition (HAI) and microneutralization (MNt) antibody assays. RESULTS. Ninety-six healthy adults (age, 18-34 years) were enrolled in the study. Arm discomfort was more common in groups that received adjuvant, but adverse effects of the vaccination were generally mild. Geometric mean serum HAI and MNt antibody titers to the influenza A/chicken/Hong Kong/G9/97 (H9N2) virus strain for all vaccine groups were similar on day 0 but were significantly higher (P<.001) on both days 28 and 56 for the MF59-adjuvanted vaccine groups than for groups given nonadjuvanted vaccine. Other measures of immunogenicity were also higher in the adjuvanted vaccine groups. HAI and MNt geometric mean titers measured after the administration of a single dose of MF59-adjuvanted vaccine were similar to those measured after 2 doses of nonadjuvanted vaccine. CONCLUSIONS The combination of MF59 adjuvant with a subunit vaccine was associated with improved immune responses to an influenza A/H9N2 virus. The adjuvanted vaccine was immunogenic even after a single dose, raising the possibility that a 1-dose vaccination strategy may be attainable with the use of adjuvanted vaccine.

[1]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[2]  Yi Guan,et al.  Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003 , 2005, Journal of Clinical Microbiology.

[3]  R. Bugarini,et al.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. , 2005, The Journal of infectious diseases.

[4]  B. Schwartz,et al.  Vaccination strategies for an influenza pandemic. , 2005, The Journal of infectious diseases.

[5]  Y. Guan,et al.  Continuing Evolution of H9N2 Influenza Viruses in Southeastern China , 2004, Journal of Virology.

[6]  M. Zambon,et al.  Confronting the avian influenza threat: vaccine development for a potential pandemic , 2004, The Lancet Infectious Diseases.

[7]  Constance Schultsz,et al.  Avian influenza A (H5N1) in 10 patients in Vietnam. , 2004, The New England journal of medicine.

[8]  A. Osterhaus,et al.  For Personal Use. Only Reproduce with Permission from the Lancet , 2022 .

[9]  N. Verlander,et al.  Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial , 2003, The Lancet.

[10]  Qi Chen,et al.  Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. , 2003, Vaccine.

[11]  E. Neumeier,et al.  Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines , 2002, Medical Microbiology and Immunology.

[12]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[13]  T. Tumpey,et al.  Immunity to Influenza A H9N2 Viruses Induced by Infection and Vaccination , 2001, Journal of Virology.

[14]  A. Podda The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[15]  R. Webster,et al.  H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. , 2001, Virology.

[16]  W. Blackwelder,et al.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. , 2001, Vaccine.

[17]  M. Peiris,et al.  Human infection with influenza H9N2 , 1999, The Lancet.

[18]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[19]  E. Lennette,et al.  Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections , 1989 .

[20]  J. L. Montagne,et al.  Summary of clinical trials of inactivated influenza vaccine - 1978. , 1983, Reviews of infectious diseases.

[21]  J. L. La Montagne,et al.  Overview of clinical trials of influenza vaccines, 1976. , 1977, The Journal of infectious diseases.